Standout Papers

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With R... 2012 2026 2016 2021 832
  1. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies (2012)
    Ranjana H. Advani, Joseph J. Buggy et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 12 from Science/Nature 75 standout
Sub-graph 1 of 20

Citing Papers

Targeting protein–ligand neosurfaces with a generalizable deep learning tool
2025 StandoutNature
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
14 intermediate papers

Works of Thomas E. Boyd being referenced

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
2012 Standout
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma
2012
and 4 more

Author Peers

Author Last Decade Papers Cites
Thomas E. Boyd 1372 1172 711 737 56 2.3k
C Jacquillat 1466 1209 583 603 55 2.5k
Soham D. Puvvada 1085 955 962 788 56 2.5k
Ellen Schlette 1307 1294 692 691 68 2.3k
Ulrich Jäger 1417 1337 523 525 85 2.4k
Stephen E. Spurgeon 1577 1294 678 792 96 2.4k
Andrew R. Pettitt 1673 1381 774 761 102 2.6k
Laurence Elias 1425 1228 799 901 72 3.2k
Sebastian Böttcher 1586 1493 677 521 76 2.8k
Elena Hartmann 1105 1446 972 663 80 2.6k
Valentin Goede 1340 1197 763 998 75 3.1k

All Works

Loading papers...

Rankless by CCL
2026